Metastatic melanoma

This phase 2 trial is testing whether a combination of two drugs, enfortumab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma that has worsened after standard therapy. The study will enroll 60 adults with unresectable stage III or IV melanoma. Researc…

This phase 2 trial tests whether adding an experimental pill (GB1211) to the immunotherapy drug pembrolizumab (Keytruda) works better than Keytruda alone for people with advanced melanoma or head and neck cancer. The study will enroll 92 participants and measure how many patients…

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

This phase 2 trial compares two ways of taking the targeted drugs dabrafenib and trametinib for advanced BRAF-mutant melanoma: continuously versus with planned breaks. About 280 people with stage III or IV melanoma that cannot be surgically removed are participating. The goal is …

This study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. By using PET/CT scans and tumor biopsies as guides, the goal is to reduce treatment side effects and burden without harmi…

This early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This phase II trial tested a combination of three drugs—pembrolizumab (Keytruda), dabrafenib (Tafinlar), and trametinib (Mekinist)—in 16 people with advanced melanoma that could not be removed by surgery. The goal was to see if a shorter course of targeted therapy, followed by im…

This phase II trial tests whether adding a growth factor (GM-CSF) to the immunotherapy drug ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that cannot be surgically removed are randomly assigned to get ipilimumab alone…

This phase II trial is testing the drug dinaciclib in 72 people with stage IV melanoma that has spread. The drug works by blocking enzymes that help cancer cells grow. Researchers are looking at side effects and whether it helps patients live longer or slows tumor growth.

This early-phase trial is testing a personalized cell therapy called lifileucel in 10 people with melanoma that has spread to the brain and is no longer responding to standard immunotherapy. Doctors remove a piece of the tumor, grow the patient's own immune cells in the lab, and …

This early-phase trial tests a new treatment for people with advanced melanoma that has stopped responding to standard immunotherapy. The treatment uses a patient's own immune cells (TILs) that have been engineered to produce a protein called IL15, combined with a drug called ace…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This study tests whether adding hydroxychloroquine (a malaria drug) to standard immunotherapy (nivolumab with or without ipilimumab) can help shrink advanced melanoma tumors. About 41 adults with stage III or IV melanoma that cannot be removed by surgery are participating. The go…

This early-phase trial tested two oral drugs, cediranib and selumetinib, in 19 people with advanced solid tumors (including melanoma) that had stopped responding to standard treatments. Cediranib works by cutting off blood supply to tumors, while selumetinib blocks a key growth s…

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This phase 3 trial tests whether the immunotherapy drug ipilimumab is better than high-dose interferon alfa-2b at preventing melanoma from coming back in patients whose cancer was removed by surgery. Over 1,600 people with high-risk stage III or IV melanoma took part. The study m…

This study tests a personalized approach to dosing two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced melanoma. Instead of giving everyone four doses, doctors will check after two doses: patients who show early benefit may stop, while those who don't can …

This study tests whether adding two targeted pills (encorafenib and binimetinib) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced melanoma that has a BRAF gene mutation. About 257 adults with untreated, advanced or spreading…

This phase 2 trial tests whether combining high-dose interleukin-2 with low-dose ipilimumab, followed by nivolumab, can shrink tumors in people with advanced melanoma that has stopped responding to prior immunotherapy. About 29 participants with inoperable stage III or IV melanom…

This study tests a new three-drug combination (tazemetostat, dabrafenib, and trametinib) in people with advanced BRAF-mutated melanoma whose cancer worsened despite prior BRAF/MEK inhibitor therapy. The goal is to find the best dose and see if the combo can slow tumor growth. Abo…

This phase III trial compares the drug pembrolizumab (MK-3475) to the current standard treatments—high-dose interferon or ipilimumab—in 1,301 patients with high-risk melanoma that has been surgically removed. The goal is to see if pembrolizumab is better at preventing the cancer …

This phase III trial compares two sequences of treatment for advanced melanoma with a BRAF mutation. One group starts with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib) if needed; the other group starts with targeted therapy the…

This study tests whether adding a drug called sargramostim to the standard immunotherapy combination of nivolumab and ipilimumab helps people with advanced melanoma live longer. About 600 patients with stage III or IV melanoma that cannot be surgically removed are participating. …

This phase 3 trial compares a subcutaneous (under-the-skin) injection of the drug combination nivolumab and relatlimab to the standard intravenous (IV) infusion in people with advanced melanoma that cannot be removed by surgery. The study aims to see if the shot delivers enough d…

This phase 2 trial tests whether adding infliximab (a drug used for arthritis) to standard immunotherapy (pembrolizumab or nivolumab+relatlimab) can prevent severe immune-related side effects in people with advanced melanoma. About 36 patients who have not had prior treatment wil…

This phase II trial is testing whether a precise, high-dose radiation treatment called stereotactic radiosurgery can control melanoma that has spread to more than three spots in the brain. The study includes 49 patients and also checks whether this approach helps preserve memory …

This early-phase trial is testing whether the immunotherapy drug nivolumab can help people with melanoma or lung cancer that has spread to the leptomeninges (the lining of the brain and spinal cord). The drug is given both through a vein and directly into the spinal fluid via a l…

This trial is investigating whether adding a short course of targeted radiation to a standard immunotherapy combination (ipilimumab and nivolumab) can improve outcomes for people with metastatic melanoma. Participants will receive the two immunotherapy drugs, and some will also r…

This study tests a treatment that uses a patient's own immune cells (T-cells) to fight advanced melanoma. Some participants also receive a dendritic cell vaccine to boost the immune response. The goal is to see if the T-cells last longer and work better against the cancer. The tr…

This study tests whether a diet rich in prebiotic foods can help the immune system better fight advanced melanoma that no longer responds to standard immunotherapy. Four adults with stage III or IV melanoma will eat a prebiotic-enriched diet while receiving a combination of two i…

This study tests a combination of three drugs—dabrafenib, trametinib, and navitoclax—in people with BRAF mutant melanoma or other solid tumors that have spread or can't be removed by surgery. The goal is to find the best dose and see how well the drugs shrink tumors. About 75 adu…

This study tested two drug combinations in 42 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal was to see if adding a second drug (GSK2141795) to trametinib could better slow cancer growth. Participants were randomly assigned to receive either tram…

This trial investigates whether combining atezolizumab (a drug that boosts the immune system) with bevacizumab (a drug that blocks blood vessel growth) can shrink tumors in people with advanced melanoma that cannot be removed by surgery or has spread. The study focuses on patient…

This phase II trial studies whether giving the immunotherapy drug pembrolizumab both before and after surgery is more effective than giving it only after surgery for patients with stage III-IV high-risk melanoma. About 313 participants will be randomly assigned to one of two trea…

This study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab can better shrink melanoma tumors before surgery and help prevent them from coming back. About 60 adults with stage III or recurrent melanoma that can be surgically removed will rece…

This phase 2 trial tests whether adding tuvusertib (a drug that blocks a DNA repair enzyme) to avelumab (an immunotherapy) can slow cancer growth in people with advanced Merkel cell cancer that didn't respond to prior treatment. About 50 participants will receive either the combi…

This early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…

This phase 2 study tests whether combining two drugs—axitinib (a targeted therapy) and ipilimumab (an immunotherapy)—can shrink tumors in people with advanced melanoma that has stopped responding to standard treatment. The trial plans to enroll 25 participants. Researchers will m…

This trial tests an experimental drug called DYP688 in people with metastatic uveal melanoma, a rare eye cancer that has spread, and other melanomas with specific genetic mutations. The study aims to find a safe dose and see whether the drug can shrink tumors. Participants receiv…

This study tests whether a precise type of radiation called SBRT can restore the effectiveness of immunotherapy drugs in people whose metastatic cancer has started to progress. About 69 adults with melanoma, lung, bladder, kidney, or head/neck cancers will receive radiation to up…

This early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors like melanoma, colorectal, ovarian, and kidney cance…

This trial investigates whether adding propranolol, a beta-blocker typically used for heart conditions, can enhance the effects of the immunotherapy drug pembrolizumab in people with advanced melanoma that cannot be removed by surgery. The study includes two phases: first to find…

This phase 1 trial tests two experimental drug combinations—AK104 or AK112 plus axitinib—in people with metastatic mucosal melanoma, a rare and hard-to-treat skin cancer. The study aims to find a safe dose and see whether the combinations shrink tumors. Participants receive the d…

This trial investigates a new type of immunotherapy for people with advanced cancers that carry a specific marker called NY-ESO-1. Researchers take a patient's own T cells, modify them in the lab to better recognize and attack cancer cells, and then infuse them back. The study al…

This early-stage study tests a new drug called belvarafenib, alone or with other drugs (cobimetinib and nivolumab), in people with advanced melanoma that has a specific NRAS gene change and has stopped responding to standard immunotherapy. The main goals are to check safety and f…

This trial investigates whether adding metformin, a common diabetes drug, to the immunotherapy pembrolizumab (Keytruda) can improve treatment for people with advanced melanoma. The study focuses on reversing metabolic problems inside tumors that may weaken immune cells. Participa…

This Phase 2 trial tests whether combining bevacizumab (Avastin) with atezolizumab (Tecentriq), with or without cobimetinib (Cotellic), can shrink or control melanoma that has spread to the brain. The study enrolls 29 adults with untreated brain metastases who are not taking ster…

This early-stage study tests whether a mix of immune-boosting drugs and targeted radiation can help the body fight advanced solid tumors that cannot be removed by surgery. About 14 adults with certain types of skin cancer, sarcoma, or breast cancer will receive the treatment dire…

This study tests whether infliximab, a drug used for inflammatory conditions, can treat colitis (colon inflammation) caused by immune checkpoint inhibitors in people with stage III or IV skin cancer. About 42 participants will receive either infliximab or steroids, and researcher…

This phase II trial is testing two different three-drug combinations in people with advanced BRAF-mutated melanoma that has spread or cannot be removed by surgery. One group receives nivolumab (immunotherapy) plus dabrafenib and trametinib (targeted therapy); the other receives n…

This early-phase trial is testing whether taking high-dose vitamin B5 (pantothenic acid) can help standard immunotherapy work better for people with advanced melanoma that cannot be surgically removed. The study includes 12 participants who have not had prior treatment for their …

This study tests whether adding focused radiation (stereotactic radiosurgery) to a combination of targeted drugs (binimetinib and encorafenib) and an immunotherapy (pembrolizumab) can better control melanoma that has spread to the brain. It includes 10 adults with a specific gene…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This early-phase trial is testing whether a ketogenic diet (low carbs, high fat) can safely help immunotherapy drugs work better in people with advanced melanoma or kidney cancer. About 60 participants will follow the diet while receiving standard immunotherapy. The main goals ar…

This phase 2 trial studies a combination of two immunotherapy drugs—talimogene laherparepvec (T-VEC) and pembrolizumab—in 43 adults with advanced melanoma that has worsened despite prior anti-PD1/L1 therapy. T-VEC is a modified virus that infects and kills cancer cells while also…

This study compares two treatments for metastatic melanoma that has spread: high-dose Interleukin-2 (IL-2) alone versus IL-2 combined with targeted radiation (SBRT). The goal is to see if adding radiation helps shrink tumors better than IL-2 alone. The trial enrolled 44 adults wi…

This study tests an inhaled form of interleukin-2 (IL-2), a protein that boosts the immune system, in people whose cancer has spread to the lungs. The goal is to find the best dose and see if it can shrink lung tumors. About 70 adults with cancers like melanoma, sarcoma, or kidne…

This phase 3 trial tests whether combining two immunotherapy drugs, fianlimab and cemiplimab, works better than the standard drug pembrolizumab for people with advanced melanoma that cannot be surgically removed. About 1,500 adults and adolescents who have not had prior treatment…

This study tests an experimental therapy called lifileucel for people with advanced melanoma that has spread or cannot be removed by surgery and has worsened after standard treatments. About 100 adults will receive their own tumor-fighting immune cells (TILs) grown in a lab. The …

This study tests whether combining two treatments—thermal ablation (using heat to destroy tumor cells) and stereotactic radiosurgery (precise, high-dose radiation)—can better control cancer that has spread to the spine and is pressing on the spinal cord. About 60 adults with vari…

This early-phase trial tests whether giving patients with advanced melanoma immune cells that have been genetically modified to resist tumor-suppressing signals can help fight the cancer. The modified T-cells are given along with high-dose Interleukin-2, a drug that boosts immune…

This phase 2 trial is testing whether giving two immunotherapy drugs, nivolumab and ipilimumab, before surgery can shrink stage III melanoma tumors and prevent the cancer from returning. The 28 participants will also receive an experimental PET scan that images immune cells to se…

This early-phase trial tests a personalized vaccine called NeoVax, combined with an immune booster (CDX-301) and standard immunotherapy drugs (nivolumab or pembrolizumab), in 10 people with advanced melanoma. The goal is to see if the combination is safe and helps the immune syst…

This early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…

This study tests whether adding tocilizumab to standard immunotherapy (ipilimumab + nivolumab) can reduce severe immune-related side effects in people with advanced melanoma that cannot be removed by surgery. About 71 participants will receive the three-drug combination during an…

This early-stage trial tests a new approach for advanced melanoma that has not responded to standard treatments. Nine patients will receive a modified virus (TILT-123) designed to deliver immune-boosting signals directly into tumors, along with their own tumor-fighting immune cel…

This early-phase trial tests a new three-drug combination for people with advanced BRAF-mutated melanoma that cannot be removed by surgery. The drugs are XL888 (an HSP90 inhibitor), vemurafenib, and cobimetinib. The main goal is to find the safest dose of XL888 when given with th…

This phase II study tests a combination of three drugs—nivolumab, ipilimumab, and cabozantinib—in 14 people with advanced melanoma that cannot be surgically removed. Participants receive the drugs for up to two years. The main goal is to see how long the cancer stays under contro…

This early-phase trial tests a new treatment for people with advanced melanoma that cannot be removed by surgery or has spread. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) grown in a lab and then given back along with a drug called ANV419 to hel…

This study tests a new two-drug combination (naporafenib + trametinib) in people with advanced NRAS-mutant melanoma that has already been treated. The goal is to see if the combo works better than standard treatments at slowing cancer growth and extending life. About 78 adults wi…

This early-stage trial tests whether giving a patient's own lab-grown tumor-fighting immune cells (Lifileucel) together with the immunotherapy drug pembrolizumab can safely shrink advanced melanoma. Only 2 people with stage IIIB-D or IV melanoma took part. The goal is to see if t…

This study tests a combination of two oral drugs, darovasertib and crizotinib, against standard treatments (immunotherapy or chemotherapy) in 420 people with a specific type of advanced eye melanoma that has spread. Participants must have a certain genetic marker (HLA-A2 negative…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This early-phase study tested a new way of giving three drugs (encorafenib, binimetinib, and nivolumab) to people with advanced BRAF-mutant melanoma. Instead of taking the drugs every day, participants followed an on/off schedule to see if it could control the cancer while reduci…

This study is for adults with advanced lung, skin, kidney, or head-and-neck cancers that have stopped responding to standard immunotherapy. The treatment combines an immune-boosting drug injected directly into a tumor, targeted radiation, and an immunotherapy drug (pembrolizumab)…

This phase 2 trial is testing whether one year of pembrolizumab (an immunotherapy drug) works as well as the standard two-year course for people with advanced melanoma that cannot be surgically removed. The study involves 29 participants in Brazil's public health system and measu…

This phase 2 trial tests a new drug called botensilimab, alone or with another drug balstilimab, in 150 people with advanced melanoma that stopped responding to prior immunotherapy. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. Researchers will …

This phase 3 trial is testing ABP 206, a biosimilar to the immunotherapy drug nivolumab (Opdivo), in 633 people with untreated advanced melanoma. The goal is to see if ABP 206 works just as well as nivolumab in shrinking tumors and extending life, while having a similar safety pr…

This study planned to test a device called NovoTTF-200A (which uses electric fields to disrupt cancer cells) together with the drug pembrolizumab in people with melanoma that had spread to the brain. The goal was to see if the combination was safe and effective. However, the stud…

This early-stage trial aimed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. STIL101 is made from a patient's own immune cells taken from their tumor, …

This early-stage trial tests a new oral drug, SX-682, combined with the immunotherapy pembrolizumab in people with advanced melanoma. The goal is to see if SX-682 can stop cancer from hiding from the immune system, making the immunotherapy work better. About 77 participants will …

This phase 2 trial is testing two experimental DNA vaccines, SCIB1 and iSCIB1+, in combination with standard immunotherapy drugs for people with advanced melanoma that cannot be removed by surgery. The study involves 173 participants and aims to see if adding these vaccines is sa…

This program provides access to the drugs trametinib and dabrafenib for adults with BRAF mutation-positive metastatic melanoma that cannot be surgically removed. Participants take dabrafenib twice daily and trametinib once daily. The goal is to offer treatment to eligible patient…

This expanded access program provides a genetically modified herpes virus (vusolimogene oderparepvec) combined with the immunotherapy drug nivolumab to adults with advanced melanoma that has worsened after anti-PD-1 treatment. The goal is to offer potential benefit to patients wh…

This study tests whether the immunotherapy drug nivolumab, alone or combined with ipilimumab, can shrink melanoma tumors that have spread to the brain. About 76 adults with stage IV melanoma and at least one brain metastasis will receive treatment. The main goal is to see how man…

This early-phase trial tests a new experimental antibody called BI-1607 alongside two existing immunotherapies (ipilimumab and pembrolizumab) in 35 people with advanced melanoma that has spread or cannot be removed. The goal is to see if the combination is safe and can shrink tum…

This early-stage trial tests a modified herpes virus (BS006) that is injected directly into tumors to kill cancer cells and activate the immune system. It involves 29 adults with advanced solid tumors like melanoma or breast cancer. The study is currently suspended, and its main …

This early-phase study tests a new drug called NBTXR3, which is injected into tumors and activated by radiation. It is combined with an immunotherapy (anti-PD-1) to see if it can help the immune system fight advanced cancers better. The study involves about 145 people with variou…

This study tests whether giving one or two immunotherapy drugs before surgery can shrink advanced melanoma (stage III or IV) that can be removed. About 48 adults with operable melanoma will receive either a single drug (dostarlimab) or a combination (dostarlimab plus cobolimab) b…

This study aimed to test a special vaccine made from modified melanoma cells to help the immune system fight remaining cancer in people with high-risk or low-burden melanoma. It was designed for patients with certain genetic markers and stages of melanoma. However, the study was …

This early-phase study tests a new way to give immunotherapy drugs (nivolumab and ipilimumab) for patients with lung cancer or melanoma that has spread to the lining of the brain and spinal cord (leptomeningeal metastases). The drugs are given both directly into the spinal fluid …

This study aimed to see if adding a healthy donor fecal transplant (FMT) to standard immunotherapy drugs could help people with advanced melanoma that no longer responds to PD-1 inhibitors. The trial was planned for about 30 participants but was withdrawn before anyone enrolled. …

This Phase 3 trial tests whether adding HBI-8000 to the immunotherapy nivolumab helps people with advanced melanoma that has not been treated with similar drugs. About 450 participants will receive either the combo or a placebo plus nivolumab. The study also includes a separate g…

This phase 2 trial tests whether adding an experimental drug (EVX-01) to standard immunotherapy (pembrolizumab) can shrink tumors better than pembrolizumab alone in people with advanced melanoma that cannot be removed by surgery. Seventeen adults who have never received checkpoin…

This study tests whether adding a new immunotherapy drug, relatlimab, to the standard drug nivolumab works better than nivolumab alone for people with advanced melanoma that has spread or cannot be removed by surgery. About 714 participants who have not had prior treatment for th…

This early-stage trial is testing an experimental drug called JSI-1187, alone or with another cancer drug (dabrafenib), in people with advanced solid tumors that have certain genetic changes. The main goal is to check safety and side effects. About 71 adults with tumors that have…

This study tests a new radioactive dye attached to tiny silica particles to improve PET scans for people with melanoma or malignant brain tumors. Ten participants will receive a single injection of the tracer to see how it spreads in the body and how much radiation it gives off. …

This study tests whether atorvastatin, a widely used cholesterol medication, can prevent melanoma from returning or spreading in people who have had high-risk melanoma surgically removed. About 150 adults with stage IIA, IIB, or IIIA melanoma will receive either atorvastatin or a…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study tests whether a supervised, home-based exercise program can help people with metastatic cancer who are starting oral targeted therapy. Participants are randomly assigned to either a weekly 60-minute session with a trained coach or to a booklet with exercise recommendat…

This study tests whether a single high dose of psilocybin (the active ingredient in magic mushrooms) combined with specialized talk therapy can help people with advanced cancer feel less anxious and more at peace. Fifteen adults with stage IV cancer will receive the treatment and…

This study follows 126 melanoma survivors who are receiving immunotherapy after surgery. Researchers will track side effects and quality of life for up to 24 months. They will also collect blood samples to look for markers that might predict who gets side effects. The goal is to …

Researchers are studying how advanced and metastatic melanoma is diagnosed and treated in everyday Spanish clinics. The study follows about 400 adults with stage III, metastatic, or unresectable melanoma from their first diagnosis. No experimental treatment is given; instead, the…

This study is testing whether a blood test that looks for tumor DNA can help doctors decide when to safely stop immunotherapy in people with advanced melanoma or non-small cell lung cancer. About 39 patients who have been on immunotherapy for at least a year and show no signs of …

This study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…

This study follows 50 adults in the UK with advanced BRAF V600 mutation-positive melanoma who are starting treatment with encorafenib and binimetinib. Instead of a controlled trial, it observes how these drugs work in real-world settings, focusing on patients' quality of life ove…

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study looks at whether the bacteria in your gut can help predict how well immunotherapy works for advanced melanoma. Researchers collected stool and blood samples from 150 patients before and during treatment. The goal is to find links between gut microbiome patterns and tre…

This study looks at whether eating a high-fiber diet can change the gut bacteria of people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a set period. The main …

This study follows 10 children in the Netherlands who received ipilimumab for advanced melanoma that had spread or could not be removed. Researchers are looking at long-term side effects and patient characteristics. The goal is to understand how safe the drug is over time in youn…

This study collects blood samples from 19 people whose metastatic melanoma or kidney cancer shrank without treatment. Researchers want to study the immune system's role in this rare event. The goal is to better understand what causes spontaneous regression, which could lead to ne…

This study aims to create a tool that can predict whether a cancer patient will benefit from their prescribed therapy. Researchers are analyzing blood samples from 10,000 people with advanced lung cancer or melanoma before and during treatment. The goal is to develop an algorithm…

This study looks at whether melanoma patients who received immunotherapy might have heart problems years later. Researchers will invite 60 people who finished treatment 2 to 10+ years ago to undergo heart tests. The goal is to see if it's possible to study these long-term side ef…

This study looks at whether a blood test (liquid biopsy) can find cancer mutations as well as the standard tissue biopsy. Researchers will compare the two methods in 1,500 advanced cancer patients to see if the blood test helps doctors choose better treatments and saves money. Th…